Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q)

A single-centre "real-world" experience

Elisa Cerqui, Annamaria Pelizzari, Francesca Schieppati, Erika Borlenghi, Chiara Pagani, Daniela Bellotti, Cinzia Lamorgese, Leonardo Boiocchi, Alessandra Sottini, Luisa Imberti, Giuseppe Rossi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

"Real life" data are needed to complement published trials on the efficacy of lenalidomide in patients with myelodysplastic syndrome (MDS) and del(5q) and on the risk of inducing acute myeloid leukemia (AML) progression. Here, we present results of lenalidomide treatment in a consecutive, population-based series of 21 red blood cell (RBC) transfusion-dependent elderly patients with multiple comorbidities. Of 18 evaluable patients (median follow-up: 22 months), 17 achieved an erythroid hematologic response (HI-E) and 16 an RBC transfusion independence. Cytogenetic response (CyR) rate was 80%, median overall survival was 48 months (range 3-164), and 5-year leukemia-free survival was 84%. Three patients progressed to AML; one, with baseline TP53 mutation, achieved HI-E, partial CyR, and did not progress to AML. Eighteen patients experienced hematological adverse events. Overall, lenalidomide was very effective and well tolerated even in unselected elderly patients with multiple comorbidities and did not appear to increase the risk of AML.

Original languageEnglish
Pages (from-to)3129-3134
Number of pages6
JournalLeukemia and Lymphoma
Volume56
Issue number11
DOIs
Publication statusPublished - Nov 2 2015

Fingerprint

Erythrocyte Transfusion
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Cytogenetics
Comorbidity
Survival
lenalidomide
Leukemia
Mutation
Population

Keywords

  • Cytogenetic response
  • del(5q) MDS
  • elderly
  • erythroid response
  • lenalidomide
  • transfusion independence

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q) : A single-centre "real-world" experience. / Cerqui, Elisa; Pelizzari, Annamaria; Schieppati, Francesca; Borlenghi, Erika; Pagani, Chiara; Bellotti, Daniela; Lamorgese, Cinzia; Boiocchi, Leonardo; Sottini, Alessandra; Imberti, Luisa; Rossi, Giuseppe.

In: Leukemia and Lymphoma, Vol. 56, No. 11, 02.11.2015, p. 3129-3134.

Research output: Contribution to journalArticle

Cerqui, E, Pelizzari, A, Schieppati, F, Borlenghi, E, Pagani, C, Bellotti, D, Lamorgese, C, Boiocchi, L, Sottini, A, Imberti, L & Rossi, G 2015, 'Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): A single-centre "real-world" experience', Leukemia and Lymphoma, vol. 56, no. 11, pp. 3129-3134. https://doi.org/10.3109/10428194.2015.1034703
Cerqui, Elisa ; Pelizzari, Annamaria ; Schieppati, Francesca ; Borlenghi, Erika ; Pagani, Chiara ; Bellotti, Daniela ; Lamorgese, Cinzia ; Boiocchi, Leonardo ; Sottini, Alessandra ; Imberti, Luisa ; Rossi, Giuseppe. / Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q) : A single-centre "real-world" experience. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 11. pp. 3129-3134.
@article{3c422a471e16413ab46e84585ff74f9e,
title = "Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): A single-centre {"}real-world{"} experience",
abstract = "{"}Real life{"} data are needed to complement published trials on the efficacy of lenalidomide in patients with myelodysplastic syndrome (MDS) and del(5q) and on the risk of inducing acute myeloid leukemia (AML) progression. Here, we present results of lenalidomide treatment in a consecutive, population-based series of 21 red blood cell (RBC) transfusion-dependent elderly patients with multiple comorbidities. Of 18 evaluable patients (median follow-up: 22 months), 17 achieved an erythroid hematologic response (HI-E) and 16 an RBC transfusion independence. Cytogenetic response (CyR) rate was 80{\%}, median overall survival was 48 months (range 3-164), and 5-year leukemia-free survival was 84{\%}. Three patients progressed to AML; one, with baseline TP53 mutation, achieved HI-E, partial CyR, and did not progress to AML. Eighteen patients experienced hematological adverse events. Overall, lenalidomide was very effective and well tolerated even in unselected elderly patients with multiple comorbidities and did not appear to increase the risk of AML.",
keywords = "Cytogenetic response, del(5q) MDS, elderly, erythroid response, lenalidomide, transfusion independence",
author = "Elisa Cerqui and Annamaria Pelizzari and Francesca Schieppati and Erika Borlenghi and Chiara Pagani and Daniela Bellotti and Cinzia Lamorgese and Leonardo Boiocchi and Alessandra Sottini and Luisa Imberti and Giuseppe Rossi",
year = "2015",
month = "11",
day = "2",
doi = "10.3109/10428194.2015.1034703",
language = "English",
volume = "56",
pages = "3129--3134",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q)

T2 - A single-centre "real-world" experience

AU - Cerqui, Elisa

AU - Pelizzari, Annamaria

AU - Schieppati, Francesca

AU - Borlenghi, Erika

AU - Pagani, Chiara

AU - Bellotti, Daniela

AU - Lamorgese, Cinzia

AU - Boiocchi, Leonardo

AU - Sottini, Alessandra

AU - Imberti, Luisa

AU - Rossi, Giuseppe

PY - 2015/11/2

Y1 - 2015/11/2

N2 - "Real life" data are needed to complement published trials on the efficacy of lenalidomide in patients with myelodysplastic syndrome (MDS) and del(5q) and on the risk of inducing acute myeloid leukemia (AML) progression. Here, we present results of lenalidomide treatment in a consecutive, population-based series of 21 red blood cell (RBC) transfusion-dependent elderly patients with multiple comorbidities. Of 18 evaluable patients (median follow-up: 22 months), 17 achieved an erythroid hematologic response (HI-E) and 16 an RBC transfusion independence. Cytogenetic response (CyR) rate was 80%, median overall survival was 48 months (range 3-164), and 5-year leukemia-free survival was 84%. Three patients progressed to AML; one, with baseline TP53 mutation, achieved HI-E, partial CyR, and did not progress to AML. Eighteen patients experienced hematological adverse events. Overall, lenalidomide was very effective and well tolerated even in unselected elderly patients with multiple comorbidities and did not appear to increase the risk of AML.

AB - "Real life" data are needed to complement published trials on the efficacy of lenalidomide in patients with myelodysplastic syndrome (MDS) and del(5q) and on the risk of inducing acute myeloid leukemia (AML) progression. Here, we present results of lenalidomide treatment in a consecutive, population-based series of 21 red blood cell (RBC) transfusion-dependent elderly patients with multiple comorbidities. Of 18 evaluable patients (median follow-up: 22 months), 17 achieved an erythroid hematologic response (HI-E) and 16 an RBC transfusion independence. Cytogenetic response (CyR) rate was 80%, median overall survival was 48 months (range 3-164), and 5-year leukemia-free survival was 84%. Three patients progressed to AML; one, with baseline TP53 mutation, achieved HI-E, partial CyR, and did not progress to AML. Eighteen patients experienced hematological adverse events. Overall, lenalidomide was very effective and well tolerated even in unselected elderly patients with multiple comorbidities and did not appear to increase the risk of AML.

KW - Cytogenetic response

KW - del(5q) MDS

KW - elderly

KW - erythroid response

KW - lenalidomide

KW - transfusion independence

UR - http://www.scopus.com/inward/record.url?scp=84947789860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947789860&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1034703

DO - 10.3109/10428194.2015.1034703

M3 - Article

VL - 56

SP - 3129

EP - 3134

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -